BUDAPEST, Hungary, June 13, 2017 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and
health of the planet, and Johnson Matthey (LN: JMAT), a global
leader in science that enables cleaner air, improved health and
more efficient use of natural resources, today announced they have
entered into an exclusive collaboration focused on the development
of microbial strains for fermentative production of peptide-based
active pharmaceutical ingredients
(APIs).
Peptide-based APIs are used as highly effective treatments in
numerous therapeutic classes. However due to their structural
complexity, peptides often are costly and difficult to produce,
requiring specialized equipment and reagents and lengthy synthetic
sequences with low chemical yields.
Through the collaboration, Intrexon will utilize its proprietary
microbial hosts and fermentation processes for expression of
peptides with high fidelity and titer. Intrexon will
concentrate on the strain generation, initial fermentation and
downstream isolation, as well as purification of the target
APIs. Following this foundational work, Johnson Matthey (JM) will be responsible for
product scale-up, formulation, and commercialization.
"Peptides are an important class of therapeutic agents and JM is
pleased to be collaborating with the Intrexon team in using their
innovative biologically-based technologies to access these
technically challenging APIs," commented Robert MacLeod, Chief Executive of JM. "Through
their strain engineering capabilities, we believe there is
significant potential for more efficient production of these
important compounds."
"As a leading provider of complex APIs and pharmaceutical
services, JM is an ideal partner for this program," said
Randal J. Kirk, Chairman and Chief
Executive Officer of Intrexon. "Their expertise and capacity,
combined with Intrexon's powerful platform for the identification,
design and engineering of production cells, should provide
significant potential for more efficient production of such
high-cost active ingredients."
Under the terms of the agreement, JM will have access to
Intrexon's technologies and expertise for microbe-based
fermentative production of specific target APIs, and Intrexon will
receive a technology access fee and reimbursement for all research
and development costs. The agreement also provides for milestone
payments to Intrexon, as well as royalties based on net sales of
commercialized products.
About Intrexon Corporation
Intrexon Corporation (NYSE:
XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products
that improve the quality of life and the health of the
planet. The Company's integrated technology suite provides
its partners across diverse markets with industrial-scale design
and development of complex biological systems delivering
unprecedented control, quality, function, and performance of living
cells. We call our synthetic biology approach Better
DNA®, and we invite you to discover more at www.dna.com
or follow us on Twitter at @Intrexon, on Facebook, and
LinkedIn.
About Johnson
Matthey
Johnson
Matthey is a global leader in science that enables a cleaner
and healthier world. With over 200-years of sustained
commitment to innovation and technological breakthroughs that
improve the function, performance and safety of our customer's
products. Our science has a global impact in areas such as low
emission transport, pharmaceuticals, chemical processing and making
the most efficient use of the planet's natural resources. Today
more than 13,000 Johnson Matthey
professionals collaborate with our network of customers and
partners to make a real difference to the world around us. For more
information, visit www.matthey.com
Inspiring science, enhancing life
Trademarks
Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information regarding Intrexon Corporation,
contact:
Investor Contact:
Christopher
Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com
Corporate Contact:
Marie
Rossi, Ph.D.
Director, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
For more information regarding Johnson Matthey, contact:
Kate Whelan
Notch Communications
+46(0) 70 238 11 49
kate.whelan@notchcommunications.co.uk
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intrexon-and-johnson-matthey-collaborate-on-fermentative-production-of-peptide-based-active-pharmaceutical-ingredients-300472701.html
SOURCE Intrexon Corporation